MXPA04001959A - Tratamiento de la demencia y trastornos de la memoria con anticonvulsivantes e. inhibidores de acetilcolinesterasa. - Google Patents

Tratamiento de la demencia y trastornos de la memoria con anticonvulsivantes e. inhibidores de acetilcolinesterasa.

Info

Publication number
MXPA04001959A
MXPA04001959A MXPA04001959A MXPA04001959A MXPA04001959A MX PA04001959 A MXPA04001959 A MX PA04001959A MX PA04001959 A MXPA04001959 A MX PA04001959A MX PA04001959 A MXPA04001959 A MX PA04001959A MX PA04001959 A MXPA04001959 A MX PA04001959A
Authority
MX
Mexico
Prior art keywords
dementia
galantamine
formula
topiramate
resulting
Prior art date
Application number
MXPA04001959A
Other languages
English (en)
Spanish (es)
Inventor
Plata-Salaman Carlos
Original Assignee
Johnson & Johnson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson & Johnson filed Critical Johnson & Johnson
Publication of MXPA04001959A publication Critical patent/MXPA04001959A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MXPA04001959A 2001-08-30 2002-08-28 Tratamiento de la demencia y trastornos de la memoria con anticonvulsivantes e. inhibidores de acetilcolinesterasa. MXPA04001959A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31597801P 2001-08-30 2001-08-30
PCT/US2002/027504 WO2003020289A1 (en) 2001-08-30 2002-08-28 Treatment of dementia and memory disorders with anticonvulsants and acetylcholinesterase inhibitors

Publications (1)

Publication Number Publication Date
MXPA04001959A true MXPA04001959A (es) 2005-02-17

Family

ID=23226936

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04001959A MXPA04001959A (es) 2001-08-30 2002-08-28 Tratamiento de la demencia y trastornos de la memoria con anticonvulsivantes e. inhibidores de acetilcolinesterasa.

Country Status (6)

Country Link
US (1) US20030060423A1 (enExample)
EP (1) EP1423127A1 (enExample)
JP (1) JP2005502680A (enExample)
CA (1) CA2459146A1 (enExample)
MX (1) MXPA04001959A (enExample)
WO (1) WO2003020289A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070053976A1 (en) * 2002-05-17 2007-03-08 Eisai R & D Management Co., Ltd. Novel combination of drugs as antidepressant
DE10235556A1 (de) * 2002-08-03 2004-02-19 Hf Arzneimittelforschung Gmbh Medikament und Verfahren zur Verringerung des Alkohol- und/oder Tabakkonsums
GB0405034D0 (en) * 2004-03-05 2004-04-07 Novartis Ag Organic compounds
MXPA06010384A (es) * 2004-03-12 2007-03-07 Egis Gyogyszergyar Nyrt Composicion farmaceutica combinada para la inhibicion de la declinacion de las funciones congnoscitivas.
TWI389709B (zh) * 2005-12-01 2013-03-21 Novartis Ag 經皮治療系統
US8278345B2 (en) 2006-11-09 2012-10-02 Probiodrug Ag Inhibitors of glutaminyl cyclase
DK2091948T3 (da) 2006-11-30 2012-07-23 Probiodrug Ag Nye inhibitorer af glutaminylcyclase
EP2098235B1 (en) * 2006-12-01 2013-08-21 Nitto Denko Corporation Method for prevention of discoloration with time of donepezil-containing skin adhesive preparation
RU2435570C2 (ru) * 2006-12-01 2011-12-10 Нитто Денко Корпорейшн Композиция для чрескожного всасывания
WO2008095221A1 (en) * 2007-02-07 2008-08-14 Gosforth Centre (Holdings) Pty Ltd Treatment of adhd
EA200901140A1 (ru) 2007-03-01 2010-04-30 Пробиодруг Аг Новое применение ингибиторов глутаминилциклазы
DK2142514T3 (da) 2007-04-18 2015-03-23 Probiodrug Ag Thioureaderivater som glutaminylcyclase-inhibitorer
WO2009145269A1 (ja) * 2008-05-30 2009-12-03 エーザイ・アール・アンド・ディー・マネジメント株式会社 経皮吸収製剤
US20110056863A1 (en) * 2008-05-30 2011-03-10 Junichi Sekiya Adhesive preparation containing donepezil, and package of the same
AU2009279372A1 (en) 2008-08-06 2010-02-11 Gosforth Centre (Holdings) Pty Ltd Compositions and methods for treating psychiatric disorders
KR101755737B1 (ko) 2009-09-11 2017-07-07 프로비오드룩 아게 글루타미닐 사이클라제의 억제제로서 헤테로사이클릭 유도체
CN109662964A (zh) 2010-02-09 2019-04-23 约翰斯.霍普金斯大学 用于改善认知功能的方法和组合物
ES2586231T3 (es) 2010-03-03 2016-10-13 Probiodrug Ag Inhibidores de glutaminil ciclasa
WO2011110613A1 (en) 2010-03-10 2011-09-15 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
WO2011143721A1 (en) * 2010-05-21 2011-11-24 Gosforth Centre (Holdings) Pty Ltd Compositions and methods for treating neurodegenerative disorders
WO2012123563A1 (en) 2011-03-16 2012-09-20 Probiodrug Ag Benz imidazole derivatives as inhibitors of glutaminyl cyclase
EP3610890A1 (en) 2012-11-14 2020-02-19 The Johns Hopkins University Methods and compositions for treating schizophrenia
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US11160785B2 (en) 2013-03-15 2021-11-02 Agenebio Inc. Methods and compositions for improving cognitive function
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
NZ738682A (en) 2015-05-22 2022-01-28 Agenebio Inc Extended release pharmaceutical compositions of levetiracetam
PL3461819T3 (pl) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej
US12208167B1 (en) * 2024-02-06 2025-01-28 Alpha Cognition Inc. Coated tablets for pH-dependent release of benzgalantamine

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI95572C (fi) * 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
AU3501697A (en) * 1996-06-28 1998-01-21 Ortho Pharmaceutical Corporation Use of topiramate or derivatives thereof for the manufacture of a medicament for the treatment of postischemic neurodegeneration
US5753693A (en) * 1996-06-28 1998-05-19 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating manic-depressive bipolar disorder
FR2757512B1 (fr) * 1996-12-24 1999-03-12 Sanofi Sa Utilisation de benzoylalkyl-1-1,2,3,6-tetrahydropyridines
US5962535A (en) * 1997-01-17 1999-10-05 Takeda Chemical Industries, Ltd. Composition for alzheimer's disease
US20020006908A1 (en) * 1998-12-03 2002-01-17 Daniel P. Van Kammen Anticonvulsant derivatives useful in treating schizophrenia
MXPA01010217A (es) * 1999-04-08 2005-09-08 Johnson & Johnson Derivados anticonvulsivos utiles en el tratamiento de trastornos neurodegenerativos cronicos.
US6420369B1 (en) * 1999-05-24 2002-07-16 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in treating dementia
WO2000072841A1 (en) * 1999-05-28 2000-12-07 Jeffrey Berlant Compounds and methods for the treatment of post traumatic stress disorder
JP2003525903A (ja) * 2000-03-03 2003-09-02 エーザイ株式会社 コリンエステラーゼ阻害剤の新規使用法
WO2002009694A1 (en) * 2000-08-02 2002-02-07 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful for the treatment of depression
KR100896971B1 (ko) * 2001-02-02 2009-05-14 오르토-맥네일 파마슈티칼, 인코퍼레이티드 프락토피라노오스 설파메이트 및 에리트로포이에틴을포함하는 신경계 기능장애 치료법
US6821979B2 (en) * 2002-03-07 2004-11-23 Blanchette Rockefeller Neurosciences Institute Synergistic enhancement of cognitive ability

Also Published As

Publication number Publication date
EP1423127A1 (en) 2004-06-02
JP2005502680A (ja) 2005-01-27
WO2003020289A9 (en) 2003-07-10
WO2003020289A1 (en) 2003-03-13
US20030060423A1 (en) 2003-03-27
CA2459146A1 (en) 2003-03-13

Similar Documents

Publication Publication Date Title
MXPA04001959A (es) Tratamiento de la demencia y trastornos de la memoria con anticonvulsivantes e. inhibidores de acetilcolinesterasa.
US9750746B2 (en) ANAVEX2-73 and certain anticholinesterase inhibitors composition and method for neuroprotection
CA2580619C (en) Use of memantine (namenda) to treat autism, compulsivity, and impulsivity
US9913836B2 (en) Anticholinergic neuroprotective composition and methods
AU782344B2 (en) Anticonvulsant derivatives useful in treating chronic neurodegenerative disorders
WO2002009694A1 (en) Anticonvulsant derivatives useful for the treatment of depression
BG106708A (bg) Пиролидинацетамидни производни самостоятелно или в комбинация за лечение на разстройства на цнс
AU2007313911A1 (en) Treatment of Pervasive Developmental Disorders
AU2005219439B2 (en) 1-aminocyclohexane derivatives for the treatment of agitation and other behavioural disorders, especially those associated with alzheimer's disease
AU768393B2 (en) Compounds and methods for the treatment of post traumatic stress disorder
MXPA04008259A (es) Co-terapia para el tratamiento de migrana que comprende derivados de un anticonvulsivo y agentes anti-migrana.
US20050090488A1 (en) Drug combination for the treatment of depression and related disorders comprising mirtazapine
AU2003226753B2 (en) Statin therapy for enhancing cognitive maintenance
AU2002323467A1 (en) Treatment of dementia and memory disorders with anticonvulsants and acetylcholinesterase inhibitors
JP2005508373A (ja) 抗痙攣剤誘導体およびカリウムを用いる共同療法を含んでなる感覚異常の処置および予防
KR20230163367A (ko) 실행 기능 장애를 치료하기 위한 조합 요법
Hazekamp et al. Clinical Studies With Cannabis and Cannabinoids, 2005-2009
CZ20022320A3 (cs) Kombinace účinných látek a její použití pro výrobu farmaceutického prostředku
MXPA06009838A (en) 1-aminovyclohexane derivatives for the treatment of agitation and other behavioral disorders, especially those associated with alzheimer’s disease
MXPA99003258A (en) Anticonvulsant derivatives useful in treating neuropathic pain

Legal Events

Date Code Title Description
FA Abandonment or withdrawal